•
Sep 30, 2024
Mink Therapeutics Q3 2024 Earnings Report
MiNK Therapeutics reported third quarter 2024 results and provided a business update.
Key Takeaways
MiNK Therapeutics reported a net loss of $1.8 million, or $0.05 per share, for the third quarter of 2024. The company ended the quarter with a cash balance of $6.3 million.
MiNK is advancing clinical programs with an ongoing Phase 2 study in second-line and later-stage gastric cancer.
Initial data from the Phase 2 study in gastric cancer is anticipated early next year.
MiNK ended the quarter with a cash balance of $6.3 million.
Net loss for the quarter was $1.8 million, or $0.05 per share.